Effects of dilution from share options (in shares) Dilutive effect of share options on weighted average number of ordinary shares Operating And Business Equipment Operating And Business Equipment [Member] Operating And Business Equipment Gross carrying amount Gross carrying amount [member] Deferred tax assets settlement Deferred Tax Assets Settlement Deferred Tax Assets Settlement Performance obligations [axis] Performance obligations [axis] Sale Of Stock [Domain] Sale Of Stock [Domain] Sale Of Stock [Domain] Average price paid per ADS (in dollar per share and euro per share) Share Repurchase Program, Average Price Per American depositary Share (ADS) Share Repurchase Program, Average Price Per American depositary Share (ADS) Treasury shares Treasury shares [member] Non-current liabilities Non-current liabilities [abstract] Segment Information Description of accounting policy for segment reporting [text block] Share-based payments (incl. long-term incentive) Key management personnel compensation, share-based payment BioNTech Europe GmbH BioNTech Europe GmbH [Member] BioNTech Europe GmbH Other non-financial liabilities Total current Other current non-financial liabilities Financial assets, category Financial assets, category [member] Non-current obligations under lease contracts Noncurrent Obligations Under Lease Contracts [Member] Noncurrent Obligations Under Lease Contracts Provisions Total current Current provisions Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets Adjustments for depreciation and amortisation expense Share of collaboration partners’ gross profit and sales milestones COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones [Member] COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones Disclosure of performance obligations [line items] Disclosure of performance obligations [line items] Repayment of loans and borrowings Repayments of borrowings, classified as financing activities Commitments under purchase agreements for property, plant and equipment Contractual commitments for acquisition of property, plant and equipment Wages and salaries Wages and salaries BioNTech Diagnostics GmbH BioNTech Diagnostics GmbH [Member] BioNTech Diagnostics GmbH Non-deductible expenses Tax effect of expense not deductible in determining taxable profit (tax loss) Contingent consideration Contingent liabilities recognised in business combination thereof allocated and un-vested (in shares) Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Expected life (in years) Option life, share options granted Cash outflow to tax authority Cash Outflow To Tax Authority Cash Outflow To Tax Authority Commercial revenues Commercial [Member] Commercial Share Repurchase Program, Tranche Two Share Repurchase Program, Tranche Two [Member] Share Repurchase Program, Tranche Two Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Ownership [Axis] Ownership [Axis] Goods and services transferred over time Goods or services transferred over time [member] State tax losses State Deferred Tax Assets Operating Loss Carryforwards State Deferred Tax Assets Operating Loss Carryforwards Financial assets - current Financial assets recognised as of acquisition date Disposals Disposals, intangible assets and goodwill Disclosure of non-adjusting events after reporting period [line items] Disclosure of non-adjusting events after reporting period [line items] Range [axis] Range [axis] Contact Personnel Email Address Contact Personnel Email Address BioNTech Research and Development, Inc. BioNTech Research and Development, Inc. [Member] BioNTech Research and Development, Inc. Production facilities Production Facilities [Member] Production Facilities Finance income Finance income Finance income Financial instruments, class Financial instruments, class [member] Purchase of intangible assets and right-of-use assets Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Trading Symbol Trading Symbol Analysis of income and expense [abstract] Valuation techniques used in fair value measurement [axis] Valuation techniques used in fair value measurement [axis] Loans and borrowings Interest Bearing Loans And Borrowings Interest Bearing Loans And Borrowings All Currencies [Domain] All Currencies [Domain] Net gain on equity instruments designated at fair value through other comprehensive income Other comprehensive income, net of tax, gains (losses) from investments in equity instruments Federal tax credits Accumulated Tax Losses In Federal Tax Credits Accumulated Tax Losses In Federal Tax Credits Share-Based Payments Disclosure of share-based payment arrangements [text block] Change in cash and cash equivalents resulting from exchange rate differences Effect of exchange rate changes on cash and cash equivalents Raw materials and supplies Current raw materials and current production supplies Total Amounts payable, related party transactions Contingent consideration Contingent consideration recognised as of acquisition date Disclosure of detailed information about property, plant and equipment [line items] Disclosure of detailed information about property, plant and equipment [line items] Interest paid and realized losses from cash and cash equivalents Interest paid, classified as operating activities Total equity and liabilities Equity and liabilities Maximum cash payment Maximum Cash Payment In Share-Based Payment Arrangement Maximum Cash Payment In Share-Based Payment Arrangement Redemption of convertible note Redemption Of Convertible Note Redemption Of Convertible Note Other Other provisions Basis of Preparation Statement of IFRS compliance [text block] Disclosure of reserves within equity [line items] Disclosure of reserves within equity [line items] Local Phone Number Local Phone Number Sean Marett Sean Marett [Member] Sean Marett Purchases Purchases, fair value measurement, liabilities Forfeited, weighted-average exercise price (in euros per share) Weighted average exercise price of share options forfeited in share-based payment arrangement Other financial liabilities Other Financial Liabilities [Member] Other Financial Liabilities Contract liabilities Current contract liabilities Temporary difference, unused tax losses and unused tax credits Temporary difference, unused tax losses and unused tax credits [member] Concessions, licenses, in-process R&D and similar rights Concessions, Licenses, In-Process Research And Development And Similar Rights [Member] Concessions, Licenses, In-Process Research And Development And Similar Rights Sales and marketing expenses Sales And Marketing Expense [Member] Sales And Marketing Expense AC Amortized Cost [Member] Amortized Cost Maturity [axis] Maturity [axis] Goods and services transferred at a point in time Goods or services transferred at point in time [member] Financial Instruments Description of accounting policy for financial instruments [text block] Cash at banks and on hand Cash Cash to be paid in 2024 Liabilities incurred Inventories Disclosure of inventories [text block] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Intangible assets with indefinite useful life Intangible assets with indefinite useful life Financial assets, class Financial assets, class [member] Equity method investment, ownership (as a percent) Equity Method Investments, Ownership Percentage Equity Method Investments, Ownership Percentage Net foreign exchange differences Adjustments for unrealised foreign exchange losses (gains) Adjustment prior year taxes Adjustments for current tax of prior periods Sales and marketing expenses Sales and marketing expenses Sales and marketing expense Number of option rights vested (in shares) Number of other equity instruments exercised or vested in share-based payment arrangement Total current liabilities Current liabilities Proposed dividends per share (in euros per share) Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share Other Other Expenses Previously held non-listed equity investment (stake of 5.3%) Previously-held Non-listed Equity Investment Previously-held Non-listed Equity Investment Useful life measured as period of time, intangible assets other than goodwill (in years) Useful life measured as period of time, intangible assets other than goodwill Document Accounting Standard Document Accounting Standard Phantom shares awarded (in shares) Key Management Personnel Compensation, Phantom Shares Awarded Key Management Personnel Compensation, Phantom Shares Awarded Other non-financial liabilities Total non-current Other non-current non-financial liabilities No Trading Symbol Flag No Trading Symbol Flag Weighted average cost of capital (as a percent) Capitalisation rate of borrowing costs eligible for capitalisation ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] Other comprehensive income Other comprehensive income [abstract] reSano GmbH reSano GmbH [Member] reSano GmbH BioNTech Idar-Oberstein Services GmbH BioNTech Idar-Oberstein Services GmbH [Member] BioNTech Idar-Oberstein Services GmbH Fair Value Measurement Description of accounting policy for fair value measurement [text block] Total identifiable net assets at fair value Identifiable assets acquired (liabilities assumed) Currency differences Currency differences Increase (decrease) through net exchange differences, intangible assets and goodwill Vesting percentage after one year (as a percent) Vesting Percentage Of Share Based Payment Arrangement Vesting Percentage Of Share Based Payment Arrangement Biopharma BioNTech Israel Ltd. Biopharma BioNTech Israel Ltd. [Member] Biopharma BioNTech Israel Ltd. Sale Of Stock [Axis] Sale Of Stock [Axis] Sale Of Stock Deferred tax liabilities Deferred tax liabilities recognised as of acquisition date Austria AUSTRIA Total non-current assets Total non-current assets Non-current assets Non tax-effective share-based payment expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Disclosure of other provisions [line items] Disclosure of other provisions [line items] Counterparty Name [Domain] Counterparty Name [Domain] Income tax assets Current tax assets, current Belgium BELGIUM -5 % Negative Five Percentage Change In Foreign Exchange Rate [Member] Negative Five Percentage Change In Foreign Exchange Rate Summary of Standards Issued but Not Yet Effective Disclosure of expected impact of initial application of new standards or interpretations [text block] Total compensation paid to key management personnel Key management personnel compensation Total Employee benefits expense Decrease / (increase) in inventories Adjustments for decrease (increase) in inventories Security Exchange Name Security Exchange Name Summary of Employee Benefits Expense Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block] Disclosure Of Detailed Information About Employee Benefits Expense Explanatory Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Contract liabilities Total Contract liabilities Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] External Business of InstaDeep External Business of InstaDeep [Member] External Business of InstaDeep More than 5 years Later than five years [member] Maximum Maximum [Member] Document Type Document Type Summary of Expense Recognized for Employee Services Received Explanation of effect of share-based payments on entity's profit or loss [text block] Reclassifications Reclassifications Of Property, Plant And Equipment Reclassifications Of Property, Plant And Equipment Other reserves Other reserves Finance expenses Finance expenses Finance costs Entity's total for consolidated structured entities [member] Entity's total for consolidated structured entities [member] Loss on derivative instruments at fair value through profit or loss Loss On Derivative Instruments At Fair Value [Member] Loss On Derivative Instruments At Fair Value Share options outstanding (in shares) Beginning balance, share options (in shares) Ending balance, share options (in shares) (Phantom) share options outstanding (expected to be allocated) (in shares) Number of share options outstanding in share-based payment arrangement Other Non-Financial Assets Disclosure of other assets [text block] Percentage of ADS to ordinary shares (as a percent) Percentage Of American Depository Shares To Ordinary Shares Percentage Of American Depository Shares To Ordinary Shares Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements Disclosure of fair value measurement of liabilities [text block] Related to release and consumption Current Onerous Contracts Provision, Related To Release And Consumption Current Onerous Contracts Provision, Related To Release And Consumption Employee Stock Option Plan Employee Stock Option Plan [Member] Employee Stock Option Plan Property, Plant and Equipment Disclosure of property, plant and equipment [text block] Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Disclosure of non-adjusting events after reporting period [table] Disclosure of non-adjusting events after reporting period [table] New Technologies Re​ New Technologies Re​ [Member] New Technologies Re​ thereof un-vested (in shares) Number Of Share Options Unested In Share-Based Payment Arrangement Number Of Share Options Unested In Share-Based Payment Arrangement Risks Risks [member] Profit or loss [abstract] Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [table] BioNTech Innovation and Services Marburg GmbH BioNTech Innovation and Services Marburg GmbH [Member] BioNTech Innovation and Services Marburg GmbH Maximum Top of range [member] Title of 12(b) Security Title of 12(b) Security Derivative Liabilities Derivative Liabilities [Member] Derivative Liabilities Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Share of collaboration partners' sales milestones COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones [Member] COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones BioNTech USA Holding, LLC BioNTech USA Holding, LLC [Member] BioNTech USA Holding, LLC Interest on lease liabilities Interest expense on lease liabilities Other Intangible Assets and Goodwill Disclosure of intangible assets and goodwill [text block] Finished goods Current finished goods Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses Effective exercise price maximum (in dollars per share) Effective Exercise Price Maximum Effective Exercise Price Maximum Cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities Corporate tax rate (as a percent) Corporate Tax Rate Corporate Tax Rate Provision related to release Current Onerous Contracts Provision, Related To Release Current Onerous Contracts Provision, Related To Release Statistical Measurement [Axis] Statistical Measurement [Axis] Summary of Goodwill Recognized Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block] Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory Other intangible assets Beginning balance Ending balance Intangible assets and goodwill Entity Interactive Data Current Entity Interactive Data Current Expected volatility Expected volatility, share options granted Construction in progress and advance payments Construction In Progress And Advance Payments [Member] Construction In Progress And Advance Payments Deferred tax liabilities have not been recognized Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised BioNTech Pharmaceuticals Spain S.L BioNTech Pharmaceuticals Spain S.L [Member] BioNTech Pharmaceuticals Spain S.L Level 1 (Fair value) Level 1 of fair value hierarchy [member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Profit attributable to ordinary equity holders of the parent for basic earnings Profit (loss), attributable to owners of parent Designated FX hedge Designated FX-Hedge Designated FX-Hedge Other financial liabilities Other non-current financial liabilities Exercise price in translation for IPO (in dollar per share and euro per share) Exercise Price Currency Translation Of Public Offering Price Per Share Exercise Price Currency Translation Of Public Offering Price Per Share Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] Summary of Number and Weighted-Average Exercise Price of Share Options Disclosure of number and weighted average exercise prices of share options [text block] Summary of Significant Unobservable Inputs Used in Fair Value Measurement Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block] Employee Stock Ownership Plan 2018 Employee Stock Ownership Plan 2018 [Member] Employee Stock Ownership Plan 2018 Weighted average fair value Weighted average fair value at measurement date, share options granted Software Computer software [member] thereof vested (in shares) Number Of Share Options Vested In Share-Based Payment Arrangement Number Of Share Options Vested In Share-Based Payment Arrangement Trade and other payables Trade and other payables Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Consideration transferred, acquired shares (as a percent) Percentage Of Consideration Transferred, Acquired Shares Percentage Of Consideration Transferred, Acquired Shares Business Combinations Disclosure of business combinations [text block] Entity Listings [Line Items] Entity Listings [Line Items] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Useful Lives Applied to the Group's Intangible Assets Disclosure of detailed information about intangible assets [text block] Non-adjusting events after reporting period Non-adjusting events after reporting period [member] Average rate Average foreign exchange rate Related Party Disclosures Disclosure of related party [text block] Percentage of voting equity interests acquired (as a percent) Percentage of voting equity interests acquired InstaDeep France SAS InstaDeep France SAS [Member] InstaDeep France SAS Fair value adjustments of financial instruments measured at fair value Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Summary of Right-of-Use Assets within Consolidated Statements of Financial Position Disclosure of quantitative information about right-of-use assets [text block] Net amount spend Share Repurchase Program, Net Amount Spent Share Repurchase Program, Net Amount Spent Auditor Location Auditor Location Other financial liabilities Other financial liabilities Income Tax Disclosure of income tax [text block] Summary of Compensation of Key Management Personnel Disclosure of information about key management personnel [text block] Classes of financial instruments [axis] Classes of financial instruments [axis] Total equity Equity at beginning of period Equity at end of period Equity Tax losses / tax credits Unused tax credits [member] Change in valuation allowance Tax Effect Of Change In Valuation Allowance Tax Effect Of Change In Valuation Allowance Unsatisfied Or Partially Unsatisfied Unsatisfied Or Partially Unsatisfied [Member] Unsatisfied Or Partially Unsatisfied Germany GERMANY Earnings per share [line items] Earnings per share [line items] Threshold amount of dividend by number of shares outstanding immediately following initial public offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Components of equity [axis] Components of equity [axis] JPT Peptide Technologies Inc. JPT Peptide Technologies Inc. [Member] JPT Peptide Technologies Inc. Considered remuneration of potential earn-out payments Considered Remuneration Of Potential Earn-out Payments Considered Remuneration Of Potential Earn-out Payments Document Shell Company Report Document Shell Company Report Net change in fair value Net Change In Fair Value Net Change In Fair Value Beginning balance, number of ordinary shares underlying options (in shares) Ending balance, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Outstanding Number Of Ordinary Shares Underlying Options Outstanding Title of Individual [Axis] Title of Individual [Axis] Level 3 (Fair value) Level 3 of fair value hierarchy [member] General and administrative expenses General and administrative expenses General and administrative expense Upfront payment, acquisition of intangible asset Upfront Payment, Acquisition of Intangible Asset Upfront Payment, Acquisition of Intangible Asset Total liabilities As of January 1, 2022 As of January 1, 2023 As of December 31, 2023 Liabilities Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods Other comprehensive income that will be reclassified to profit or loss, net of tax Cost of sales Cost of sales Cost of sales 1 to 5 years Later than one year and not later than five years [member] Weighted average exercise price (€) Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Aggregated measurement [member] Aggregated measurement [member] Money market funds Money Market Fund [Member] Money Market Fund U.S. dollar United States of America, Dollars State tax credits Accumulated Tax Losses In State Tax Credits Accumulated Tax Losses In State Tax Credits Percentage of target share price applicable for prior twelve month period (as a percent) Percentage Of Target Share Price Applicable For Prior Twelve Month Percentage Of Target Share Price Applicable For Prior Twelve Month Recognized directly in equity Deferred tax relating to items credited (charged) directly to equity BioNTech (Shanghai) Pharmaceuticals Co. Ltd. BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. Property, plant and equipment, useful life (in years) Useful life measured as period of time, property, plant and equipment Tax rate effect Tax rate effect from change in tax rate Weighted average share price (in euros per share) Weighted average share price, share options granted Lease liabilities Lease liabilities [member] Other financial assets Other current financial assets Loans and borrowings Loans And Borrowings [Member] Loans And Borrowings Provisions Disclosure of provisions [text block] BioNTech Real Estate Verwaltungs GmbH BioNTech Real Estate Verwaltungs GmbH [Member] BioNTech Real Estate Verwaltungs GmbH Advance payments Advance Payments [Member] Advance Payments Net cash flows from / (used in) financing activities Cash flows from (used in) financing activities Disclosure of performance obligations [table] Disclosure of performance obligations [table] thereof vested, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Employee Equity Plan Employee Equity Plan [Member] Employee Equity Plan Cash and cash equivalents Cash and cash equivalents recognised as of acquisition date Customer-related intangible assets recognised as of acquisition date Customer-related intangible assets recognised as of acquisition date Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block] Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory Other operating equipment Other Operating Equipment [Member] Other Operating Equipment Total depreciation charge Depreciation, right-of-use assets Issued Capital and Reserves Disclosure of share capital, reserves and other equity interest [text block] Other reserves Other reserves [member] Summary of Cash and Cash Equivalents Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block] Disclosure Of Cash And Cash Equivalents Explanatory Schedule of Other Financial Commitments Disclosure of commitments [text block] Unobservable inputs [member] Unobservable inputs [member] Summary of Revenue Recognized Disclosure Of Recognition Of Revenue Explanatory [Table Text Block] Disclosure Of Recognition Of Revenue Explanatory Share Repurchase Program, Tranche One Share Repurchase Program, Tranche One [Member] Share Repurchase Program, Tranche One Reclassifi-cation Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Interest received and realized gains from cash and cash equivalents Interest received, classified as operating activities Classes of financial liabilities [axis] Classes of financial liabilities [axis] Contract liabilities Contract Liabilities [Member] Contract Liabilities Expense arising from equity-settled share-based payment arrangements Expense from equity-settled share-based payment transactions Other Non-Financial Liabilities [Abstract] Other Non-Financial Liabilities Share repurchase program Share Repurchase Program Classified As Financing Activities Share Repurchase Program Classified As Financing Activities Financial liabilities, class Financial liabilities, class [member] COVID-19 vaccine revenues COVID-19 Vaccine Revenues [Member] COVID-19 Vaccine Revenues Summary of Information about Entity with Significant Influence Over Group Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block] Disclosure Of Entity With Significant Influence Over Group Explanatory Other comprehensive income / (loss) for the period, net of tax Other comprehensive income (loss) Other comprehensive income InstaDeep Tunisia SARL InstaDeep Tunisia SARL [Member] InstaDeep Tunisia SARL Current obligations under lease contracts Current Obligations Under Lease Contracts [Member] Current Obligations Under Lease Contracts Transaction costs Share issue related cost Non-current Non-current lease liabilities Entity Emerging Growth Company Entity Emerging Growth Company United Kingdom UNITED KINGDOM Income tax liabilities Current tax liabilities, non-current Change in fair value with increasing input factor (in millions €) Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Statement of financial position [abstract] Disclosure of reconciliation of liabilities arising from financing activities [line items] Disclosure of reconciliation of liabilities arising from financing activities [line items] Expense / (Income) arising from cash-settled share-based payment arrangements Expense from cash-settled share-based payment transactions Classes of share capital [axis] Classes of share capital [axis] Purchase of shares under agreement (in shares) Purchase Of Shares Under Agreement Purchase Of Shares Under Agreement Applicable wage taxes and social security contributions resulting from and withheld upon exercise Payables on social security and taxes other than income tax BioNTech Innovation GmbH BioNTech Innovation GmbH [Member] BioNTech Innovation GmbH Line items by function [member] Line items by function [member] Fixed assets Fixed Assets [Member] Fixed Assets Inventories Total Current inventories BioNTech Delivery Technologies GmbH BioNTech Delivery Technologies GmbH [Member] BioNTech Delivery Technologies GmbH Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Ranges [member] Ranges [member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code 1 to 5 years Later than two years and not later than five years [member] Types of risks [axis] Types of risks [axis] Other operating income Miscellaneous other operating income BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. Aggregated time bands Aggregated time bands [member] +5 % Positive Five Percentage Change In Foreign Exchange Rate [Member] Positive Five Percentage Change In Foreign Exchange Rate AT Impf GmbH AT Impf GmbH [Member] AT Impf GmbH Business Contact Business Contact [Member] Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss Summary of Financial Liabilities at Amortized Cost Disclosure of financial liabilities [text block] Hedging instruments [axis] Hedging instruments [axis] Financial Assets and Financial Liabilities Disclosure of offsetting of financial assets and financial liabilities [text block] External Product Sales of JPT External Product Sales To JPT [Member] External Product Sales To JPT Foreign exchange forward contracts Derivatives [member] Buildings Buildings [member] Equity Equity [abstract] Cumulative depreciation and impairment charges Accumulated depreciation, amortisation and impairment [member] Fixed compensation Key Management Personnel Compensation, Fixed Compensation Key Management Personnel Compensation, Fixed Compensation Interest income Interest income BioNTech Australia Pty Ltd. BioNTech Australia Pty Ltd. [Member] BioNTech Australia Pty Ltd. Inventories Description of accounting policy for measuring inventories [text block] Share-based payments Share-based payment arrangements [member] Decrease in corporate tax rate (as a percent) Decrease In Corporate Tax Rate Decrease In Corporate Tax Rate Revenues from Contracts with Customers Disclosure of revenue from contracts with customers [text block] Financial Liabilities at Fair Value Through Other Comprehensive Income, Category Financial Liabilities At Fair Value Through Other Comprehensive Income, Category [Member] Financial Liabilities At Fair Value Through Other Comprehensive Income, Category Foreign exchange differences, net Foreign Exchange Differences [Member] Foreign Exchange Differences Estimated milestone payment to be received Estimated Milestone Payment To Be Received At Contract Inception Estimated Milestone Payment To Be Received At Contract Inception Cash-Settled Share-Based Payment Arrangement Cash-Settled Share-Based Payment Arrangement [Member] Cash-Settled Share-Based Payment Arrangement Other Other Current Assets, Other Other Current Assets, Other Share repurchase program authorized amount Share Repurchase Program Authorized Amount Share Repurchase Program Authorized Amount Change in cash and cash equivalents resulting from other valuation effects Effect Of Other Valuation Changes On Cash And Cash Equivalents Effect Of Other Valuation Changes On Cash And Cash Equivalents Beginning balance Ending balance Liabilities arising from financing activities Document Transition Report Document Transition Report Pfizer (COVID-19 vaccine) Pfizer (COVID-19 vaccine) [Member] Pfizer (COVID-19 vaccine) Prepayment for future development activities Prepayment For Future Development Activities Prepayment For Future Development Activities Property, plant and equipment [member] Property, plant and equipment [member] Other non-financial assets Total current Other current non-financial assets Entity's total for related parties Entity's total for related parties [member] Reclassification for share-based payment arrangement Reclassification Of Share-Based Payment Arrangement Reclassification Of Share-Based Payment Arrangement Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] BioNTech Real Estate Holding GmbH BioNTech Real Estate Holding GmbH [Member] BioNTech Real Estate Holding GmbH LTI-plus program Employee Equity Plan, Long-Term Incentive Plus Program [Member] Employee Equity Plan, Long-Term Incentive Plus Program Current income taxes Current tax expense (income) Liquidity risk Liquidity risk [member] Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Entity Address, Country Entity Address, Country Other Other Income Expense [Member] Other Income Expense Diluted earnings for the period per share (in euros per share) Diluted profit for the period per share (in euros per share) Diluted earnings (loss) per share Inventory write-offs Inventory write-down Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets [Abstract] Vesting [Domain] Vesting Period [Domain] Vesting Period Additional provisions, other provisions Additional provisions, other provisions Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations Earnings per share [text block] Performance obligations [member] Performance obligations [member] Business Combinations [Abstract] Business Combinations 1 [Abstract] Business Combinations 1 Consideration Acquisition-date fair value of total consideration transferred [abstract] Refund liabilities Current refunds provision Acquisition of subsidiaries and businesses Acquisitions through business combinations, intangible assets and goodwill Disclosure of transactions between related parties [line items] Disclosure of transactions between related parties [line items] CGU Immunotherapies CGU Immunotherapies [Member] CGU Immunotherapies Increase of research and development expense Increase (Decrease) Of Research And Development Expense Increase (Decrease) Of Research And Development Expense German Federal Ministry of Health German Federal Ministry of Health [Member] German Federal Ministry of Health Contingent consideration Contingent consideration [member] Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Prepayments related to CRO and CMO contracts Current advances to suppliers Granted, share options (in shares) Number of share options granted in share-based payment arrangement Increase (decrease) in intangible assets Increase (decrease) in intangible assets and goodwill BioNTech UK Ltd. BioNTech UK Ltd. [Member] BioNTech UK Ltd. Customers Customers [member] Currency differences Increase (decrease) through net exchange differences, property, plant and equipment Goodwill from the acquisition Goodwill recognised as of acquisition date Summary of Amounts Recognized in Consolidated Statement of Operations Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory Document Period End Date Document Period End Date Summary of Transactions Between Other Related Parties Disclosure of transactions between related parties [text block] Tax rate for deferred taxes (as a percent) Tax Rate On Deferred Taxes Tax Rate On Deferred Taxes Options outstanding, weighted-average expected life (in years) Weighted average remaining contractual life of outstanding share options Contractual obligation to acquire intangible assets Contractual commitments for acquisition of intangible assets Standards Issued but Not Yet Effective Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block] Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory Beginning balance, weighted-average exercise price (in euros per share) Ending balance, weighted-average exercise price (in euros per share) Weighted-average exercise price (in euros per share) Weighted average exercise price of share options outstanding in share-based payment arrangement BioNTech Taiwan Co. Ltd. BioNTech Taiwan Co. Ltd. [Member] BioNTech Taiwan Co. Ltd. Corporate tax Accumulated Tax Losses In Corporate Tax Accumulated Tax Losses In Corporate Tax Disclosure of quantitative information about right-of-use assets [line items] Disclosure of quantitative information about right-of-use assets [line items] Business combinations [axis] Business combinations [axis] Shares issued (in shares) Number of instruments or interests issued or issuable Classes of liabilities [axis] Classes of liabilities [axis] Announcement Of Research, Development And Commercialization Collaboration Agreement Announcement Of Research, Development And Commercialization Collaboration Agreement [Member] Announcement Of Research, Development And Commercialization Collaboration Agreement DeepChain Technology DeepChain Technology [Member] DeepChain Technology Property, plant and equipment Property, plant and equipment, beginning balance Property, plant and equipment, ending balance Property, plant and equipment Vesting Period [Axis] Vesting Period [Axis] Vesting Period Net increase / (decrease) in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Total cash outflow for leases Cash outflow for leases Entity's total for subsidiaries [member] Entity's total for subsidiaries [member] Short-term incentive – first installment Key management personnel compensation, short-term employee benefits Fair value measurement derivative Accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss Loans and borrowings Interest Bearing Loans And Borrowings [Member] Interest Bearing Loans And Borrowings Other variable compensation Key Management Personnel Compensation, Other Variable Compensation Key Management Personnel Compensation, Other Variable Compensation Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Associates [axis] Associates [axis] Deferred tax assets Deferred tax assets Treasury shares (in shares) Number Of Shares Held In Treasury Number Of Shares Held In Treasury Forfeited, share options (in shares) Number of share options forfeited in share-based payment arrangement Minimum strike price (as a percent) Exercise Of Option Rights, Minimum Strike Price Percent Exercise Of Option Rights, Minimum Strike Price Percent Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Automobiles Vehicles [member] Proceeds from sale of property, plant and equipment Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Cash at banks and on hand Cash At Banks And On Hand [Member] Cash At Banks And On Hand Other non-financial assets Total non-current Other non-current non-financial assets Purchases of property and other assets from entities controlled by ATHOS KG Purchases of property and other assets, related party transactions Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Statement of cash flows [abstract] Government Grants Description of accounting policy for government grants [text block] Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Comprehensive income for the period, net of tax Comprehensive income Total Other non-financial assets Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents as of December 31 Total Cash and cash equivalents Listed equity investments Listed Equity Investments [Member] Listed Equity Investments Increase of general and administrative expense Increase (Decrease) Of General And Administrative Expense Increase (Decrease) Of General And Administrative Expense Document Annual Report Document Annual Report Recognized directly in equity Increase (decrease) through business combinations, deferred tax liability (asset) Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name Closing rate Closing foreign exchange rate Total non-current liabilities Non-current liabilities Cash-settled option rights, exercised (in shares) Exercised, share options (in shares) Share options, exercised (in shares) Number of share options exercised in share-based payment arrangement Cover [Abstract] Cash and Cash Equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Total assets Assets United States United States UNITED STATES Valuation adjustment Valuation Adjustment [Member] Valuation Adjustment Earnings per share Basic earnings per share [abstract] Change in fair value with decreasing input factor (in millions €) Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Total consideration Assets Acquired (Liabilities Assumed), Including Goodwill Assets Acquired (Liabilities Assumed), Including Goodwill Price of ADS as a percentage of exercise price, maximum (as a percent) Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Foreign exchange differences, net Net foreign exchange gain Total consideration Consideration transferred, acquisition-date fair value Financing activities Cash flows from (used in) financing activities [abstract] Settled (in shares) Number Of Share Options Settled In Share-based Payment Arrangement Number Of Share Options Settled In Share-based Payment Arrangement Working capital adjustments: Working Capital Adjustments [Abstract] Working Capital Adjustments Depreciation Depreciation, property, plant and equipment Other Non-Financial Liabilities Disclosure of other liabilities [text block] Increase of sales and marketing expense Increase (Decrease) Of Sales And Marketing Expense Increase (Decrease) Of Sales And Marketing Expense Share capital Issued capital [member] Entity Current Reporting Status Entity Current Reporting Status Option to purchase ordinary shares (in shares) Number of instruments granted in share-based payment arrangement Refund liabilities Refunds provision Other sales Other Sales [Member] Other Sales Retained earnings Retained earnings Basis of Consolidation Disclosure of basis of consolidation [text block] Consolidated structured entities [axis] Consolidated structured entities [axis] Property, plant and equipment Property, plant and equipment recognised as of acquisition date Disclosure of Provisions Disclosure Of Provisions [Table Text Block] Disclosure Of Provisions Weighted average number of ordinary shares outstanding for basic EPS (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Total Intangible Assets With Indefinite Useful Life And Goodwill Intangible Assets With Indefinite Useful Life And Goodwill Right-of-use assets Right-of-use assets [member] License And Option Agreement [Member] License And Option Agreement [Member] License And Option Agreement Tax losses Unused tax losses [member] Option rights exercisable period (in years) Option Exercisable Period Option Exercisable Period Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Scenario [Domain] Scenario [Domain] BioNTech Manufacturing GmbH BioNTech Manufacturing GmbH [Member] BioNTech Manufacturing GmbH Current liabilities Current liabilities [abstract] Liabilities Liabilities [member] Finance income excluding foreign exchange differences Adjustments for finance income BioNTech Cell & Gene Therapies GmbH BioNTech Cell & Gene Therapies GmbH [Member] BioNTech Cell & Gene Therapies GmbH Entity Voluntary Filers Entity Voluntary Filers Significant Accounting Policies Disclosure of material accounting policy information [text block] Statistical Measurement [Domain] Statistical Measurement [Domain] Income tax paid Income taxes paid (refund), classified as operating activities Liability related to the phantom option awards Phantom Option Awards, Liability Phantom Option Awards, Liability Summary of Fair Values of Identifiable Net Assets Disclosure of detailed information about business combination [text block] Cash And Cash Equivalents [Line Items] Cash And Cash Equivalents 1 [Line Items] Cash And Cash Equivalents 1 Change in deferred taxes due to tax rate change Tax effect from change in tax rate Contract assets Contract assets Share capital Share capital [member] Share-based payments Share based Payments, Classified As Operating Activities Share based Payments, Classified As Operating Activities Operating income Profit (loss) from operating activities Disclosure of financial assets [line items] Disclosure of financial assets [line items] Effects Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Research and development expenses Research And Development Expenses [Member] Research And Development Expenses Number of shares outstanding (in shares) Number of shares outstanding Income taxes Income taxes Income taxes Tax expense (income) Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1 Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member] Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share Other operating expenses Other operating expenses Miscellaneous other operating expense Provision related to usage Current Onerous Contracts Provision, Related To Usage Current Onerous Contracts Provision, Related To Usage Geographical [Axis] Geographical [Axis] Ryvu Therapeutics S.A. Ryvu Therapeutics S.A. [Member] Ryvu Therapeutics S.A. Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Management Board Management Board [Member] Management Board Trade tax Accumulated Tax Losses In Trade Tax Accumulated Tax Losses In Trade Tax BioNTech Individualized mRNA Manufacturing GmbH BioNTech Individualized mRNA Manufacturing GmbH [Member] BioNTech Individualized mRNA Manufacturing GmbH InstaDeep Employee Incentive Plan InstaDeep Employee Incentive Plan [Member] InstaDeep Employee Incentive Plan Non-current assets Non-current assets [abstract] Total Contractual capital commitments One year Share-Based Payment Arrangement, Year One [Member] Share-Based Payment Arrangement, Year One Medine GmbH Medine GmbH [Member] Medine GmbH Gain on derivative instruments at fair value through profit or loss Gain On Derivative Instruments At Fair Value Through Profit Or Loss [Member] Gain On Derivative Instruments At Fair Value Through Profit Or Loss Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Security investments Securities Investment [Member] Provisions Total non-current Non-current provisions Expense related to short-term leases and leases of low-value assets Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Trade and other receivables Trade and other current receivables Short-term incentive – second installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment State income tax with average rate (as a percent) Effective tax rate Average effective tax rate Intangible assets and goodwill Intangible assets and goodwill [member] Earnings per Share Disclosure of earnings per share [text block] Share capital Issued capital Estimated allocation date 2024 Estimated Allocation Date Two [Member] Estimated Allocation Date Two Sales to collaboration partners COVID-19 Vaccine, Sales To Collaboration Partners [Member] COVID-19 Vaccine, Sales To Collaboration Partners Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [table] Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Prof. Ugur Sahin, M.D. Professor Ugur Sahin MD [Member] Professor Ugur Sahin MD Carrying amount At fair value [member] Treasury Shares Description of accounting policy for treasury shares [text block] Contract liabilities Non-current contract liabilities Other assets non-current and current Other Assets Non-current And Current Recognised As Of Acquisition Date Other Assets Non-current And Current Recognised As Of Acquisition Date Pfizer (Zoster) Pfizer (Zoster) [Member] Pfizer (Zoster) Government grants Government Grants [Member] Government Grants Other effects Other tax effects for reconciliation between accounting profit and tax expense (income) Deviation due to local tax basis Tax Effect Of Deviation Due To Local Tax Basis Tax Effect Of Deviation Due To Local Tax Basis Basic earnings for the period per share (in euros per share) Basic profit for the period per share (in euros per share) Basic earnings (loss) per share Remeasurement gain on defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Summary of Inventories Disclosure Of Classes Of Inventories Explanatory [Table Text Block] Disclosure Of Classes Of Inventories Explanatory Contact Personnel Fax Number Contact Personnel Fax Number Percentage of exercise price increase (as a percent) Percentage Of Increase In Exercise Price Percentage Of Increase In Exercise Price Other financial assets Other Financial Assets [Member] Other Financial Assets Other (incl. deferred expenses) Other Deferred Taxes [Member] Other Deferred Taxes InstaDeep DE GmbH InstaDeep DE GmbH [Member] InstaDeep DE GmbH General and administrative expenses General And Administrative Expenses [Member] General And Administrative Expenses Summary of Information about Parent Company Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block] Disclosure Of Significant Investments By Parent Company Explanatory Foreign exchange forward contracts Derivative financial liabilities Forecast Forecast [Member] Share-based payment expenses Adjustments for share-based payments Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049 Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Research and Development Expenses Description of accounting policy for research and development expense [text block] Income and Expenses Disclosure Of Income And Expense Explanatory [Text Block] Disclosure Of Income And Expense Explanatory Reclassifications Increase (decrease) through transfers and other changes, intangible assets and goodwill Licenses Licences [member] Summary of Other Assets Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Assets Explanatory Cash Dividend Description of accounting policy for dividends [text block] Sierk Poetting, Ph.D. Doctor Sierk Poetting [Member] Doctor Sierk Poetting Impairment of Non-Financial Assets Description of accounting policy for impairment of non-financial assets [text block] Business Combinations and Goodwill Description of accounting policy for business combinations and goodwill [text block] LTI 2021 program Employee Equity Plan, Long-Term Incentive 2021 Program [Member] Employee Equity Plan, Long-Term Incentive 2021 Program Proceeds from maturity of other financial assets (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities Weighted average share price (in euros per share) Weighted average share price BioNTech 2020 Employee Equity Plan for Employees Based Outside North America BioNTech Employee Equity Plan For Employees Based In Europe [Member] BioNTech Employee Equity Plan For Employees Based In Europe Effects from tax losses and tax credits Tax effect of tax losses Product and Service [Domain] Product and Service [Domain] Loss on disposal of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment Total Expense from share-based payment transactions with employees Timing of transfer of goods or services [axis] Timing of transfer of goods or services [axis] Current assets Current assets [abstract] Contingencies and other financial commitments Disclosure of commitments and contingent liabilities [text block] Categories of related parties [axis] Categories of related parties [axis] Earnings per share [table] Earnings per share [table] Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] ATHOS KG ATHOSKG [Member] ATHOSKG Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Reverse Repo Reverse Repo [Member] Reverse Repo Intellectual property rights Intellectual Property Rights [Member] Intellectual Property Rights Statement of changes in equity [line items] Statement of changes in equity [line items] Solidarity surcharge rate (as a percent) Solidarity Surcharge Rate Solidarity Surcharge Rate Entity's total for associates [member] Entity's total for associates [member] Classes of financial assets [axis] Classes of financial assets [axis] BioNTech Innovative Manufacturing Services GmbH BioNTech Innovative Manufacturing Services GmbH [Member] BioNTech Innovative Manufacturing Services GmbH Other Increase (decrease) through other changes, liabilities arising from financing activities Assets Assets [abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Deviation due to deviating income tax rate (Germany and foreign countries) Tax effect of foreign tax rates Entity File Number Entity File Number Other financial assets Other non-current financial assets BioNTech R&D (Austria) GmbH BioNTech R&D (Austria) GmbH [Member] BioNTech R&D (Austria) GmbH Investing activities Cash flows from (used in) investing activities [abstract] Profit for the period Profit for the period Profit (loss) Auditor Firm ID Auditor Firm ID Contractual disputes Legal proceedings provision Entity Shell Company Entity Shell Company LTI 2020 program Employee Equity Plan, Long-Term Incentive 2020 Program [Member] Employee Equity Plan, Long-Term Incentive 2020 Program InstaDeep Nigeria Limited InstaDeep Nigeria Limited [Member] InstaDeep Nigeria Limited BioNTech BioNTainer Holding GmbH BioNTech BioNTainer Holding GmbH [Member] BioNTech BioNTainer Holding GmbH Treasury shares used for acquisition of business combination Treasury Shares Used For Acquisition Of Business Combination Treasury Shares Used For Acquisition Of Business Combination Litigation costs Litigation Costs [Member] Litigation Costs Research and development expense (as a percent) Percentage Of Research And Development Expense Percentage Of Research And Development Expense Taxes Description of accounting policy for income tax [text block] Non-listed equity investments Non-Listed Equity Investments [Member] Non-Listed Equity Investments Cash outflow for share based payment exercise Cash Outflow For Share Based Payment Arrangement Exercise Cash Outflow For Share Based Payment Arrangement Exercise Inventories Inventories 1 [Member] Inventories 1 Technology-based intangible assets recognised as of acquisition date Technology-based intangible assets recognised as of acquisition date Unfinished goods Current work in progress thereof allocated and vested but subject to performance and waiting requirements (in shares) Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement InstaDeep Ltd. InstaDeep Ltd [Member] InstaDeep Ltd Exercise price (in euros per share) Exercise price, share options granted General and administrative expense (as a percent) Percentage Of General And Administrative Expense Percentage Of General And Administrative Expense Current and deferred taxes Current And Deferred Tax Expense (Income) Current And Deferred Tax Expense (Income) Statement of changes in equity [abstract] Decrease cost of sales Increase (Decrease) Cost Of Sales Increase (Decrease) Cost Of Sales Contact Personnel Name Contact Personnel Name American Depositary Shares, each Representing one ordinary share American Depositary Shares Each Representing One Ordinary Share [Member] American Depositary Shares Each Representing One Ordinary Share Subsidiaries Subsidiaries [member] Statutory tax rate (as a percent) Applicable tax rate Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Document Registration Statement Document Registration Statement Entity Address, Address Line One Entity Address, Address Line One FVTPL Fair Value Through Profit Or Loss [Member] Fair Value Through Profit Or Loss Federal corporate income tax (as a percent) Federal Corporate Income Tax Federal Corporate Income Tax Pension costs Post-employment benefit expense in profit or loss, defined benefit plans Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Assets [member] Assets [member] Summary of Detailed Information About Intangible Assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] BioNTech Sénégal Suarl BioNTech Sénégal Suarl [Member] BioNTech Sénégal Suarl Summary of Finance Expense Disclosure Of Finance Cost Explanatory [Table Text Block] Disclosure Of Finance Cost Explanatory Audit Information [Abstract] Audit Information Current Current lease liabilities Share-based payments Increase (decrease) through share-based payment transactions, equity Trade payables and other payables Trade Payables And Other Payables [Member] Trade Payables And Other Payables Unobservable inputs [axis] Unobservable inputs [axis] Shares transferred (approx. 1.1 million shares) Equity interests of acquirer Remaining upfront fees contract liabilities Remaining Upfront Fees Contract Liabilities Remaining Upfront Fees Contract Liabilities Other financial liabilities Other current financial liabilities Share-Based Payments Description of accounting policy for share-based payment transactions [text block] Total Other non-financial liabilities Leases [Abstract] Leases 1 [Abstract] Leases 1 Operating activities Cash flows from (used in) operating activities [abstract] Within one year Less than 1 year Not later than one year [member] Revenue recognition applying the sales-based or usage-based royalty recognition constraint model Sales Based Or Usage Based Royalty Recognition Constraint Model [Member] Sales Based Or Usage Based Royalty Recognition Constraint Model Leases Description of accounting policy for leases [text block] More than one year Later than one year [member] Summary of Changes in Liabilities Arising from Financing Activities Disclosure of reconciliation of liabilities arising from financing activities [text block] Total current assets Current assets Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Bad debt expense has been recognized Expense recognised during period for bad and doubtful debts for related party transaction Other liabilities long-term and short-term Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date Other related parties Other related parties [member] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Manufacturing Variances Manufacturing Variances [Member] Manufacturing Variances Decrease / (increase) in trade and other receivables, contract assets and other assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding BioNTech BioNTech [Member] BioNTech Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Other provisions Other provisions [member] Social security costs Social security contributions Acquisition of subsidiaries and businesses Acquisitions through business combinations, property, plant and equipment Share Repurchase Program Period [Axis] Share Repurchase Program Period [Axis] Share Repurchase Program Period Risk-free interest rate Risk free interest rate, share options granted Research & development revenues Research And Development [Member] Research And Development Discount rate Discount rate, measurement input [member] Purchases of various goods and services from entities controlled by ATHOS KG Purchases Of Goods And Service Related Party Transactions Purchases Of Goods And Service Related Party Transactions Other Other Liabilities, Other Other Liabilities, Other Cash paid Cash transferred Total amounts recognized in profit or loss Lease Expenses Recognized In Profit Or Loss Lease Expenses Recognized In Profit Or Loss Right-of-use assets Right-Of-Use Assets Recognised As Of Acquisition Date Right-Of-Use Assets Recognised As Of Acquisition Date Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits [Member] Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Write-downs (reversals of write-downs) of inventories Write-downs (reversals of write-downs) of inventories Categories of financial assets [axis] Categories of financial assets [axis] Liabilities arising from financing activities Liabilities arising from financing activities [member] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Medilink Therapeutics (Suzhou) Co. Ltd., Medilink Therapeutics (Suzhou) Co. Ltd., [Member] Medilink Therapeutics (Suzhou) Co. Ltd., Trade and other receivables Trade receivables [member] Net employee defined benefit liabilities Net Employee Defined Benefit Liabilities [Member] Net Employee Defined Benefit Liabilities Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods Other comprehensive income that will not be reclassified to profit or loss, net of tax Effect on pre-tax equity Foreign Currency Changes Effect On Pretax Equity Foreign Currency Changes Effect On Pretax Equity BioNTech Switzerland GmbH BioNTech Switzerland GmbH [Member] BioNTech Switzerland GmbH Intangible assets Identifiable intangible assets recognised as of acquisition date Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Management Board Grant Management Board Grant [Member] Management Board Grant Cash outflow Expense from share-based payment transactions Issuance of share capital Issueance of share capital Issue of equity Disclosure of reserves within equity [table] Disclosure of reserves within equity [table] European Commission To Collaboration Partner European Commission To Collaboration Partner [Member] European Commission To Collaboration Partner Deferred taxes Deferred tax expense (income) Assets Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] Lease liabilities, loans and borrowings Non-current Lease Liabilities, Loans And Borrowings Non-current Lease Liabilities, Loans And Borrowings Measurement [axis] Measurement [axis] thereof un-vested, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement Property, Plant and Equipment Description of accounting policy for property, plant and equipment [text block] Deferred tax liabilities Deferred tax liabilities Option rights vesting period (in years) Option Vesting Period Option Vesting Period Impairment loss for a reduction of future cash flows (as a percent) Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Other Non-Financial Assets [Abstract] Other Non-Financial Assets Proceeds from loans and borrowings Proceeds from borrowings, classified as financing activities Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of reconciliation of liabilities arising from financing activities [table] Exercise price of phantom options granted (in euro per share) Exercise Price, Phantom Options Granted Exercise Price, Phantom Options Granted Summary of Accumulated Tax Losses Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block] Disclosure Of Accumulated Tax Losses Explanatory Chief Executive Officer Grant Chief Executive Officer Grant [Member] Chief Executive Officer Grant Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Total revenues Revenue from contracts with customers Duality Biologics (Suzhou) Co. Ltd., Duality Biologics (Suzhou) Co. Ltd., [Member] Duality Biologics (Suzhou) Co. Ltd., Minimum Bottom of range [member] Payments related to lease liabilities Payments of lease liabilities, classified as financing activities Sales and marketing expense (as a percent) Percentage Of Sales And Marketing Expense Percentage Of Sales And Marketing Expense New leases and disposals Increase through new leases, liabilities arising from financing activities Direct product sales to customers COVID-19 Vaccine, Direct Product Sales To Customers [Member] COVID-19 Vaccine, Direct Product Sales To Customers Net (gain) / loss on derivative instruments at fair value through profit or loss Gains (losses) on financial liabilities at fair value through profit or loss thereof un-vested, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement Cost of sales Cost of sales [member] Non tax-effective income Tax Effect, Non Tax Effective Income Tax Effect, Non Tax Effective Income Entity Filer Category Entity Filer Category Ordinary shares Ordinary shares [member] Current Fiscal Year End Date Current Fiscal Year End Date InstaDeep Ltd. InstaDeep Ltd. [Member] InstaDeep Ltd. Summary of Contract Balances Disclosure Of Contract Balances From Contracts With Customers Explanatory [Table Text Block] Disclosure Of Contract Balances From Contracts With Customers Explanatory Summary of Other Operating Expenses Disclosure Of Other Operating Expenses Explanatory [Table Text Block] Disclosure Of Other Operating Expenses Explanatory Supervisory Board Supervisory Board [Member] Supervisory Board Inventories [Abstract] Inventories [Abstract] Inventories [Abstract] Liabilities to employees Liabilities For Employee Benefits Liabilities For Employee Benefits Address Type [Domain] Address Type [Domain] Advance payment received for future COVID 19 vaccine sale Advance Payment Received For Future COVID-19 Vaccine Sale Advance Payment Received For Future COVID-19 Vaccine Sale Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Adjustments to reconcile profit before tax to net cash flows: Adjustments to reconcile profit (loss) [abstract] LTI Program Employee Equity Plan, Long-Term Incentive Program [Member] Employee Equity Plan, Long-Term Incentive Program Tax-effective equity transaction costs Tax Effective Equity Transaction Costs Tax Effective Equity Transaction Costs Amounts included in contract liabilities at the beginning of the year Revenue that was included in contract liability balance at beginning of period Liabilities from share-based payment arrangements Liabilities from share-based payment transactions BioNTech US Inc. BioNTech US Inc. [Member] BioNTech US Inc. Entity Listings [Table] Entity Listings [Table] Estimated allocation date 2025 Estimated Allocation Date Three [Member] Estimated Allocation Date Three Monetary assets in U.S. dollar Monetary Assets [Member] Monetary Assets Forfeited, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Medigene Immunotherapies GmbH Medigene Immunotherapies GmbH [Member] Medigene Immunotherapies GmbH Cash flow projections Cash Flow Projections, Measurement Input [Member] Cash Flow Projections, Measurement Input BioNTech Manufacturing Marburg GmbH BioNTech Manufacturing Marburg GmbH [Member] BioNTech Manufacturing Marburg GmbH Retained earnings Accumulated other comprehensive income [member] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses InstaDeep LLC InstaDeep LLC [Member] InstaDeep LLC Significant unobservable input, liabilities Significant unobservable input, liabilities Additions Additions other than through business combinations, intangible assets other than goodwill Group Information Disclosure of composition of group [text block] Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Corporate Information Disclosure Of Corporate Information Explanatory [Text Block] Disclosure Of Corporate Information Explanatory Earnings per share Earnings per share [abstract] Cash and cash equivalents in U.S. dollar Cash And Cash Equivalents 1 [Member] Cash And Cash Equivalents 1 Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Long-term deposits Long-term deposits Financial assets at amortised cost, category Financial assets at amortised cost, category [member] Summary of Shares Repurchase Program Disclosure of Shares Repurchase Program [Table Text Block] Disclosure of Shares Repurchase Program Finance expense excluding foreign exchange differences Adjustments for finance costs Movements in government grants Adjustments For Movements In Government Grants Adjustments For Movements In Government Grants Recognized in OCI Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Number of share options held (in shares) Number Of Share Options Held Number Of Share Options Held Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] Recognized in P&L Deferred tax expense (income) recognised in profit or loss FVTOCI Fair Value Through OCI [Member] Fair Value Through OCI Thereof deferred tax assets Thereof Deferred Tax Assets [Member] Thereof Deferred Tax Assets Dividends Dividends paid, classified as financing activities Dividends paid, classified as financing activities Statement of changes in equity [table] Statement of changes in equity [table] Goodwill Goodwill [member] Proceeds from issuance of share capital and treasury shares, net of costs Proceeds from issuing shares Summary of Other Non-Financial Liabilities Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory Net cash flows from operating activities Cash flows from (used in) operating activities Document Fiscal Period Focus Document Fiscal Period Focus Trade receivables Trade Receivables Recognised As Of Acquisition Date Trade Receivables Recognised As Of Acquisition Date Estimated allocation date 2026 Estimated Allocation Date Four [Member] Estimated Allocation Date Four Revenue from Contracts with Customers Description of accounting policy for recognition of revenue [text block] City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Deferred tax (assets) and liabilities, net recognized Beginning balance deferred tax assets net Ending balance deferred tax assets net Deferred tax liability (asset) Lease liabilities, loans and borrowings Current Lease Liabilities, Loans And Borrowings Current Lease Liabilities, Loans And Borrowings Summary of Disaggregation of Revenues from Contracts with Customers Disclosure of disaggregation of revenue from contracts with customers [text block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] BioNTech Rwanda Ltd. BioNTech Rwanda Ltd. [Member] BioNTech Rwanda Ltd. Allocation date May 2023 Estimated Allocation Date One [Member] Estimated Allocation Date One Summary of Other Operating Income Disclosure Of Other Operating Income Explanatory [Table Text Block] Disclosure Of Other Operating Income Explanatory Current onerous provision addition Current Onerous Contracts Provision, Additions Current Onerous Contracts Provision, Additions Currency risk Currency risk [member] Treasury shares Treasury shares Summary of Standards Applied for the First Time Disclosure of initial application of standards or interpretations [text block] Equipment, tools and installations Equipment, Tools And Installations [Member] Equipment, Tools And Installations Federal tax losses Federal Deferred Tax Assets Operating Loss Carryforwards Federal Deferred Tax Assets Operating Loss Carryforwards Jens Holstein Jens Holstein [Member] Jens Holstein Pfizer Inc. Pfizer Inc [Member] Pfizer Inc Obligations from onerous CMO contracts Current onerous contracts provision Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Dividends Dividends recognised as distributions to owners Disclosure of financial assets [table] Disclosure of financial assets [table] NT Security and Services GmbH NT Security and Services GmbH [Member] NT Security and Services GmbH Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Liabilities Explanatory Research and development expenses Research and development expenses Research and development expense Fair value adjustments of financial instruments measured at fair value Fair Value Adjustments Of Financial Instruments Measured At Fair Value Fair Value Adjustments Of Financial Instruments Measured At Fair Value Summary of Inputs Used in Measurement of Fair Value at Grant Date Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Costs of inventories Cost of inventories recognised as expense during period Trade and other receivables Trade And Other Receivables [Member] Trade And Other Receivables Ownership [Domain] Ownership [Domain] Financial liabilities, category [member] Financial liabilities, category [member] Capital reserve Capital reserve Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss Disclosure of financial assets [text block] Exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH [Member] JPT Peptide Technologies GmbH Currency [Axis] Currency [Axis] Acquisition of subsidiaries and businesses, net of cash acquired Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Entity Address, City or Town Entity Address, City or Town Outstanding balances of related party transactions Provisions for doubtful debts related to outstanding balances of related party transaction Summary of Current and Deferred Tax Expense Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block] Disclosure Of Current And Deferred Tax Expense Explanatory Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] Summary of Finance Income Disclosure Of Finance Income Explanatory [Table Text Block] Disclosure Of Finance Income Explanatory Right-of-use assets Right-of-use assets Lease liabilities Lease liabilities Lease liabilities Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Maximum economic benefits of options exercised Maximum Economic Benefits Of Options Exercised Maximum Economic Benefits Of Options Exercised Income And Expenses By Nature [Axis] Income And Expenses By Nature [Axis] Income And Expenses By Nature Deferred expenses Deferred Expense Deferred Expense Financial liabilities Financial liabilities Financial liabilities Revenues Revenue [abstract] Cash-settled related to rights vested and exercisable Share Based Payment Arrangement, Related To Rights Vested And Exercisable Share Based Payment Arrangement, Related To Rights Vested And Exercisable Total assets Assets Recognised As Of Acquisition Date Assets Recognised As Of Acquisition Date Income tax liabilities Current tax liabilities, current Right-of-use assets, useful life (in years) Useful Life Measured As Period Of Time, Right-Of-Use Assets Useful Life Measured As Period Of Time, Right-Of-Use Assets BioNTech Restricted Stock Unit Plan for North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member] BioNTech 2020 Restricted Stock Unit Plan For North America Employees Number of ordinary shares underlying options Number Of Ordinary Shares Underlying Options [Abstract] Number Of Ordinary Shares Underlying Options Liabilities [Roll Forward] Liabilities [Roll Forward] Liabilities Non-tax effective bargain purchase Non Tax Effective Bargain Purchase Non Tax Effective Bargain Purchase Share options outstanding Share Options Outstanding [Abstract] Share Options Outstanding Growth rate used to extrapolate cash flow projections (as a percent) Growth rate used to extrapolate cash flow projections Standards Applied for the First Time Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block] Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory Additions Additions other than through business combinations, property, plant and equipment Level 2 (Fair value) Level 2 of fair value hierarchy [member] Liabilities arising from financing activities [axis] Liabilities arising from financing activities [axis] Provisions Description of accounting policy for provisions [text block] Title of Individual [Domain] Title of Individual [Domain] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Leases Disclosure of leases [text block] Total liabilities Liabilities Recognised As Of Acquisition Date Liabilities Recognised As Of Acquisition Date Summary of Number and Share Price of Restricted Stock Units Disclosure of number and weighted average exercise prices of other equity instruments [text block] Thereof deferred tax liability Thereof Deferred Tax Liability [Member] Thereof Deferred Tax Liability Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) Disclosure of performance obligations [text block] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] % equity interest Ownership of ordinary shares in BioNTech (in %) Proportion of ownership interest in subsidiary Exercised, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Additions to right-of-use assets Additions to right-of-use assets Purchase of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities Number of share options exercisable in share-based payment arrangement (in shares) Number of share options exercisable in share-based payment arrangement Expected tax credit Tax expense (income) at applicable tax rate Goodwill Goodwill Subsidiaries [axis] Subsidiaries [axis] Share repurchase program Share Repurchase Program, Repurchased During Period, Value Share Repurchase Program, Repurchased During Period, Value Summary of Estimated Useful Lives of the Assets or Shorter Lease Term Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block] Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory Entity Registrant Name Entity Registrant Name Liabilities Liabilities [abstract] Financial liabilities at amortised cost, category Financial liabilities at amortised cost, category [member] Biotheus Inc., Biotheus Inc., [Member] Biotheus Inc., Disclosure of reconciliation of changes in intangible assets and goodwill [table] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Auditor Name Auditor Name Summary of Carrying Amount of Monetary Assets Disclosure Of Foreign Currency Risk Explanatory [Table Text Block] Disclosure Of Foreign Currency Risk Explanatory Non cash current tax relating to items credited (charged) directly to equity Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity Employee Stock Ownership Plan Employee Stock Ownership Plan [Member] Employee Stock Ownership Plan Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Multi-period excess earnings method Multi-period excess earnings method [member] Trade payables and other payables Trade and other current payables Entity Central Index Key Entity Central Index Key Equity and liabilities Equity and liabilities [abstract] Disclosure of contingent liabilities [line items] Disclosure of contingent liabilities [line items] Sales tax receivable Receivables from taxes other than income tax Financial assets at fair value through other comprehensive income, category Net gain on equity instruments designated at fair value through other comprehensive income Financial assets at fair value through other comprehensive income, category [member] Summary of Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Upfront payment Upfront Payment Upfront Payment Cash equivalents Cash equivalents Related Party [Abstract] Related Party [Abstract] Related Party [Abstract] Number of ADSs purchased (in shares) Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination [line items] Other non-cash income / (loss) Other adjustments for non-cash items Total Cash And Cash Equivalent Cash And Cash Equivalent Summary of Deferred Taxes Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Foreign exchange differences, net Net foreign exchange loss Timing of transfer of goods or services Timing of transfer of goods or services [member] Trade and other receivables Current trade receivables Shares issued (in shares) Number of shares issued Hedging instruments Hedging instruments [member] Equity Equity [member] Amendment Flag Amendment Flag Significant Accounting Judgements, Estimates and Assumptions Disclosure of accounting judgements and estimates [text block] Transaction costs Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Summary of Effect of Changes in Foreign Exchange Rates Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block] Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory BioNTech Delivery Technologies (US), LLC BioNTech Delivery Technologies (US), LLC [Member] BioNTech Delivery Technologies (US), LLC Intangible Assets Description of accounting policy for intangible assets and goodwill [text block] LTI 2022 program Employee Equity Plan, Long-Term Incentive 2022 Program [Member] Employee Equity Plan, Long-Term Incentive 2022 Program Share Repurchase Program 2023 Share Repurchase Program 2023 [Member] Share Repurchase Program 2023 Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Total Purchases From Related Party Transactions Purchases From Related Party Transactions Monetary liabilities and provisions in U.S. dollar Monetary Liability And Provisions [Member] Monetary Liability And Provisions Convertible note – embedded derivative Convertible Note, Embedded Derivative [Member] Convertible Note, Embedded Derivative Exercised, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement Classes of intangible assets and goodwill [axis] Classes of intangible assets and goodwill [axis] Valuation techniques [member] Valuation techniques [member] Carrying amount Carrying amount [member] thereof vested, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Summary of Information about Subsidiaries Disclosure of subsidiaries [text block] Disposals Disposals, property, plant and equipment Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine [Member] Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Current versus Non-Current Classifications Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block] Description Of Accounting Policy For Assets And Liabilities Explanatory Investment in other financial assets Other cash payments to acquire interests in joint ventures, classified as investing activities Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Amortization Accumulated Depreciation, Amortisation And Impairment Accumulated Depreciation, Amortisation And Impairment Classes of assets [axis] Classes of assets [axis] Foreign Currencies Description of accounting policy for foreign currency translation [text block] Other additional provisions Current Onerous Contracts Provision, Other Additional Provisions Current Onerous Contracts Provision, Other Additional Provisions Issuance of treasury shares Issuance Of Share Capital Issuance Of Share Capital Capital reserve Capital reserve [member] Cost of sales (as a percent) Percentage Of Cost Of Sales Percentage Of Cost Of Sales Scenario [Axis] Scenario [Axis] Profit before tax Profit before tax Profit before tax Profit (loss) before tax Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Disclosure of quantitative information about right-of-use assets [table] Disclosure of quantitative information about right-of-use assets [table] Property, plant and equipment [abstract] Property, plant and equipment [abstract] Payment terms in contracts with customers Description of significant payment terms in contracts with customers Effect on profit / (loss) before tax Foreign Currency Changes Effect On Loss, Before Tax Foreign Currency Changes Effect On Loss, Before Tax Net cash flows used in investing activities Cash flows from (used in) investing activities Land and buildings Land and buildings [member] Bank deposits Bank Deposits [Member] Bank Deposits Entity's total for business combinations Entity's total for business combinations [member] All levels of fair value hierarchy [member] All levels of fair value hierarchy [member] Statement of comprehensive income [abstract] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Major customers [axis] Major customers [axis] Financial assets Financial assets BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi [Member] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi Total Provisions Liabilities from wage taxes and social securities expenses Liabilities From Wage Taxes And Social Securities Expenses Liabilities From Wage Taxes And Social Securities Expenses OncoC4 Inc. OncoC4 Inc. [Member] OncoC4 Inc. Events After the Reporting Period Disclosure of events after reporting period [text block] Categories of financial liabilities [axis] Categories of financial liabilities [axis] Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share